Aslan Chemical

ASLAN Pharmaceuticals was a clinical-stage immunology-focused biopharmaceutical company that developed innovative treatments for inflammatory diseases and oncology. The company's lead program was eblasakimab (ASLAN004), a first-in-class monoclonal antibody targeting the IL-13 receptor alpha 1 subunit for the treatment of moderate-to-severe atopic dermatitis. Its second major asset, farudodstat (ASLAN003), was a potent oral DHODH inhibitor being evaluated for autoimmune conditions such as alopecia areata. Despite promising clinical data, the company faced significant financial headwinds and announced its voluntary liquidation in July 2024. ASLAN was headquartered in Singapore with operations in the United States. The company was previously listed on the Nasdaq under the symbol ASLN.